Search results for " Combination"

showing 10 items of 923 documents

Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications.

2012

Objectives To investigate the premorbid use of secondary prevention medications in patients with recurrent vascular events. Design Prospective, observational, population based study. Setting The Dijon Stroke Registry and the registry of myocardial infarction of Dijon and Cote d9Or, France. Patients All patients with cerebral ischaemia (ischaemic stroke or transient ischaemic attacks) or coronary artery disease (CAD) and a history of vascular disease (cerebral ischaemia, CAD or peripheral arterial disease (PAD)) in Dijon, France from 2006 to 2010. Main outcome measures Data on medical history and prior use of treatments were collected. Mutivariate analyses were performed to identify predicto…

Malemedicine.medical_specialtyCoronary Artery DiseaseTransient ischaemic attacksBrain IschemiaCoronary artery diseasePeripheral Arterial DiseaseFibrinolytic AgentsRisk FactorsInternal medicinemedicineSecondary PreventionHumansMedical historycardiovascular diseasesMyocardial infarctionProspective StudiesRegistriesStrokeAntihypertensive AgentsAgedAged 80 and overVascular diseasebusiness.industryMiddle Agedmedicine.diseaseDrug UtilizationSurgeryPsychiatry and Mental healthRegimenSurgeryDrug Therapy CombinationFemaleNeurology (clinical)FranceHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessFibrinolytic agentJournal of neurology, neurosurgery, and psychiatry
researchProduct

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refr…

2000

Background: Diuretics, have been accepted as first-line treatment in refractory heart failure, but a lack of response is a frequent event. A randomised single blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory NYHA class IV congestive heart failure (CHF). Materials and methods: Sixty patients (21 F/39 M) with refractory CHF (NYHA class IV) of different etiologies, unresponsive to high oral doses of furosemide, ACE-inhibitors, digitalis, and nitrates, aged 65–90 years, were enrolled. They had to have an ejection fraction (EF) < 35%, serum creatinine < 2 mg/dl, B…

Malemedicine.medical_specialtyDiuresisBlood PressurePotassium Chloridechemistry.chemical_compoundBolus (medicine)FurosemideHeart RateHumansMedicineSingle-Blind MethodDiureticsInfusions IntravenousAgedAged 80 and overHeart FailureSaline Solution HypertonicCreatinineEjection fractionbusiness.industryBody WeightSodiumFurosemideMiddle Agedmedicine.diseaseHypokalemiaDiuresisUric AcidSurgerychemistryCreatinineAnesthesiaHeart failurePotassiumDrug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessHyponatremiamedicine.drugEuropean Journal of Heart Failure
researchProduct

Giant hepatic hydatid cyst as a cause of small bowel obstruction.

2006

Today, giant hydatid cysts are fairly rare even in endemic areas. We describe a case of an extremely large hydatid cyst of the liver that was causing massive compression of the neighboring organs, giving rise to a subocclusive syndrome of the intestine. After considering the various approaches available for the treatment of this disease, it was decided that radical surgery was still the best therapeutic choice, especially when extremely large cysts are involved. In particular, in clinical situations where it is difficult to perform radical surgical procedures, less aggressive surgery followed by drug treatment should be the treatment of choice.

Malemedicine.medical_specialtyEchinococcosis Hepaticalanine aminotransferase aspartate aminotransferase contrast mediumoral contraceptive agentHelminthiasisAntiprotozoal AgentsHydatid cystHepatic ComplicationAlbendazoleAggressive surgeryDrug treatmentparasitic diseasesIntestine SmallmedicineHumansRadical surgeryAgedbusiness.industryGeneral Medicinemedicine.diseaseEchinococcosisSurgeryBowel obstructionSettore MED/18 - Chirurgia GeneraleDrug Therapy CombinationbusinessTomography X-Ray ComputedIntestinal Obstruction
researchProduct

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

2010

AIM Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin. MATERIAL AND METHODS Overall, 28 insulin-naive type 2 diabetes subjects (mean +/- SD age, 61.5 +/- 6.7 years; diabetes duration, 9.8 +/- 6.5 years; HbA1c, 7.1 +/- 0.5%; BMI, 30.7 +/- 4.3 kg/m(2)) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentInsulin IsophaneInsulin GlarginePilot ProjectsNPH insulinType 2 diabetesNPH insulinDrug Administration ScheduleEndocrinologyInsulin-Secreting CellsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinintact proinsulinGlycated Hemoglobinbusiness.industryInsulin glargineInsulindigestive oral and skin physiologynutritional and metabolic diseasesFastingOriginal ArticlesMiddle AgedPostprandial Periodmedicine.diseaseMetforminMetforminInsulin Long-ActingEndocrinologyPostprandialDiabetes Mellitus Type 2beta cell stressDrug Therapy CombinationFemalebusinessmedicine.drugBlood samplingDiabetes, Obesity and Metabolism
researchProduct

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (C…

2021

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma. We report the first results for nivolumab plus chemotherapy versus chemotherapy alone.In this multicentre, randomised, open-label, phase 3 trial (CheckMate 649), we enrolled adults (≥18 years) with previously untreated, unresectable, non-HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, …

Malemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentIpilimumabAdenocarcinoma030204 cardiovascular system & hematologyGastroenterologyCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineProgression-free survivalImmune Checkpoint InhibitorsAgedChemotherapybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseProgression-Free SurvivalOxaliplatinNivolumabFluorouracilAdenocarcinomaDrug Therapy CombinationFemaleEsophagogastric JunctionNivolumabbusinessmedicine.drugThe Lancet
researchProduct

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV–HIV-coinfected patients receiving ribavirin combined with a first-generati…

2017

Background We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV–HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC). Methods Patients of the ANRS HC27 BocepreVIH study were genotyped for two ITPA single nucleotide polymorphisms involved in ITPA deficiency. RBV trough concentration (Ctrough) was determined at week (W)4 and W8. Impact of ITPA deficiency on anaemia, RBV Ctrough, response and haematotoxicity (grade 3/4 anaemia, erythropoietin [EPO] use, RBV dose reduction or transfusion between day [D]0 and W8) was evaluated. Impact of RBV Ctrough on anaemia…

Malemedicine.medical_specialtyGenotype[SDV]Life Sciences [q-bio]Human immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeAntiviral AgentsGastroenterologychemistry.chemical_compoundPharmacotherapyGene FrequencyRisk FactorsInternal medicineRibavirinmedicineHumansGenetic Predisposition to DiseasePharmacology (medical)PyrophosphatasesAllelesComputingMilieux_MISCELLANEOUSPharmacologyCoinfectionbusiness.industryRibavirinAnemiaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFirst generation3. Good health[SDV] Life Sciences [q-bio]Infectious DiseaseschemistryMutationCoinfectionDrug Therapy CombinationFemaleITPAbusinessMetabolism Inborn ErrorsINOSINE TRIPHOSPHATASE
researchProduct

Effect of antibiotic treatment on vegetation size and complication rate in infective endocarditis

1997

Background: Infective endocarditis is associated with significant morbidity and mortality, with valvular destruction, and with congestive heart failure. Embolic events are more common in patients with echocardiographically discernible vegetations, especially when vegetations are >10 mm in diameter. Hypothesis: The objective of the study was to follow vegetation morphology during native valve endocarditis, to compare it with the clinical course and antibiotic treatment chosen, and to evaluate whether the impact on vegetation size and complication rate of antibiotic regimens differed in patients with positive and negative blood cultures. Methods: The effect of different antibiotic regimes on …

Malemedicine.medical_specialtyHeart diseasemedicine.drug_classAortic Valve InsufficiencyAntibioticsThromboembolismmedicineHumansEndocarditisClinical InvestigationSurvival rateGram-Positive Bacterial InfectionsRetrospective StudiesNative Valve Endocarditisbusiness.industryMitral Valve InsufficiencyEndocarditis BacterialGeneral MedicineMiddle Agedmedicine.diseaseAnti-Bacterial AgentsCerebral AngiographySurgerySurvival RateTreatment OutcomeInfective endocarditisDrug Therapy CombinationFemaleMorbiditymedicine.symptomGram-Negative Bacterial InfectionsCardiology and Cardiovascular MedicinebusinessVegetation (pathology)ComplicationEchocardiography TransesophagealFollow-Up StudiesClinical Cardiology
researchProduct

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-[alpha]2b: A Randomized Trial

2009

BACKGROUND Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. OBJECTIVE To evaluate use of peginterferon-alpha2a plus ribavirin to re-treat nonresponders to peginterferon-alpha2b plus ribavirin. DESIGN Randomized, parallel-group trial conducted between September 2003 and February 2007. Patients and researchers were not blinded to intervention assignment. Random assignment was centralized, computer-generated, and stratified by geographic region, hepatitis C virus (HCV) genotype, and histologic diagnosis. SETTING 106 international centers. PATIENTS 950 nonresponders to 12 or more weeks of therapy with peginterferon-alpha2b plus ribav…

Malemedicine.medical_specialtyHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawPegylated interferonInternal medicineRibavirinInternal Medicineretreatment non responder hepatitis CHumansMedicineTreatment FailureNot evaluatedbusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesSurgerychemistryRetreatmentRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

2009

Treatment with peginterferon alfa and ribavirin produces a sustained virologic response (SVR) in approximately 60% of hepatitis C virus (HCV)-infected patients. Alternate options are needed for patients who relapse or do not respond to therapy.This prospective, international, multicenter, open-label study evaluated efficacy and safety of peginterferon alfa-2b (1.5 microg/kg/wk) plus weight-based ribavirin (800-1400 mg/day) in 2333 chronic HCV-infected patients with significant fibrosis/cirrhosis whose previous interferon alfa/ribavirin therapy failed. Patients with undetectable HCV-RNA at treatment week (TW) 12 received 48 weeks of therapy; patients with detectable HCV-RNA at TW12 could ent…

Malemedicine.medical_specialtyHepatitis C virusPeginterferon-alfaHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPharmacotherapyInternal medicineRibavirinmedicineHCV ANTIVIRAL THERAPYHumansTreatment FailureInterferon alfaHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseaseschemistryImmunologyRNA ViralPeginterferon alfa-2bDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct

Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA).

2014

SummaryAcute pulmonary embolism (PE) is a serious complication in association with malignant diseases. We describe the successful treatment of PE applying a systemic thrombolytic therapy in a 4-year-old boy with acute lymphoblastic leukaemia.The thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) 0.1 mg/ kg bodyweight per hour for six hours was continued for six days without important side effects. In particular no bleeding complications were observed. Computed tomography with contrast revealed a remarkable regression of the central PE. Without further delays the chemotherapy was resumed.

Malemedicine.medical_specialtyLeukemia T-Cellmedicine.medical_treatmentComputed tomographyFibrinolytic AgentsmedicineHumansRecombinant tissue plasminogen activatorChemotherapymedicine.diagnostic_testbusiness.industryAnticoagulantsHematologyHeparin Low-Molecular-Weightmedicine.diseaseRecombinant ProteinsSurgeryPulmonary embolismTreatment OutcomeChild PreschoolTissue Plasminogen ActivatorLymphoblastic leukaemiaDrug Therapy CombinationbusinessComplicationPulmonary EmbolismT cell leukaemiaHamostaseologie
researchProduct